{"content":"<li class=\"n-box-item date-title\" data-end=\"1570507199\" data-start=\"1570420800\" data-txt=\"Monday, December 23, 2019\">Monday, October  7, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3504349\" data-ts=\"1570486386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVM\" target=\"_blank\">CVM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504349-cel-sciminus-2_4-amid-report-misleading-on-therapy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cel-Sci -2.4% amid report it&#39;s misleading on therapy</a></h4><ul>   <li>Cel-Sci (NYSEMKT:<a href='https://seekingalpha.com/symbol/CVM' title='CEL-SCI Corporation'>CVM</a>) is <font color=\"red\">down 2.4%</font> postmarket after Stat News' Adam Feuerstein posts a <a href=\"https://www.statnews.com/2019/10/07/a-cancer-company-has-misled-investors-repeatedly-about-its-drug-its-time-for-some-truth-telling/\" target=\"_blank\">critical piece</a> on the company's disclosures about its immunotherapy Multikine.</li>    <li>The company has \"misled investors repeatedly\" about the treatment, which is \"still destined to fail. (In fact, it already has.)\"</li>    <li>Last January Feuerstein said a Phase 3 clinical trial was doomed to a negative outcome, but says his error was not appreciating the extent to which the company would issue \"a steady flow of misleading and erroneous information.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504349\" data-linked=\"Cel-Sci -2.4% amid report it&#39;s misleading on therapy\" data-tweet=\"$CVM - Cel-Sci -2.4% amid report it&#39;s misleading on therapy https://seekingalpha.com/news/3504349-cel-sciminus-2_4-amid-report-misleading-on-therapy?source=tweet\" data-url=\"https://seekingalpha.com/news/3504349-cel-sciminus-2_4-amid-report-misleading-on-therapy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504346\" data-ts=\"1570483938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504346-ambarella-leads-after-hour-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ambarella leads after hour losers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/NAT' title='Nordic American Tankers Limited'>NAT</a> <font color=\"green\">+2.2%</font>. <a href='https://seekingalpha.com/symbol/EYE' title='National Vision Holdings, Inc.'>EYE</a> <font color=\"green\">+2.1%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella, Inc.'>AMBA</a> <font color=\"red\">-11.7%</font>. <a href='https://seekingalpha.com/symbol/QGEN' title='QIAGEN N.V.'>QGEN</a> <font color=\"red\">-6.4%</font>. <a href='https://seekingalpha.com/symbol/AQN' title='Algonquin Power & Utilities Corp.'>AQN</a> <font color=\"red\">-3.9%</font>. <a href='https://seekingalpha.com/symbol/CVM' title='CEL-SCI Corporation'>CVM</a> <font color=\"red\">-3.5%. </font><a href='https://seekingalpha.com/symbol/GES' title='Guess&#39;, Inc.'>GES</a> <font color=\"red\">-2.0%</font>. <a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a> <font color=\"red\">-1.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504346\" data-linked=\"Ambarella leads after hour losers\" data-tweet=\"$NAT $EYE $AMBA - Ambarella leads after hour losers https://seekingalpha.com/news/3504346-ambarella-leads-after-hour-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3504346-ambarella-leads-after-hour-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504339\" data-ts=\"1570482257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBA\" target=\"_blank\">AMBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504339-ambarellaminus-11_5-chinese-customer-hits-blacklist\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ambarella -11.5% as Chinese customer hits blacklist</a></h4><ul>   <li>Ambarella (NASDAQ:<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella, Inc.'>AMBA</a>) has <font color=\"red\">slid 11.5%</font> after its customer Hangzhou Hikvision was one of a number of Chinese companies put on a blacklist by the Trump administration.</li>    <li>Hikvision is thought to account for a percentage of revenues in the high teens for Ambarella.</li>    <li>Shares had fallen 1.5% during the regular session.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504339\" data-linked=\"Ambarella -11.5% as Chinese customer hits blacklist\" data-tweet=\"$AMBA - Ambarella -11.5% as Chinese customer hits blacklist https://seekingalpha.com/news/3504339-ambarellaminus-11_5-chinese-customer-hits-blacklist?source=tweet\" data-url=\"https://seekingalpha.com/news/3504339-ambarellaminus-11_5-chinese-customer-hits-blacklist\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504305\" data-ts=\"1570477050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504305-pg-and-e-wildfire-victims-reportedly-to-see-13_5b-in-claims\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E wildfire victims reportedly to see $13.5B in claims</a></h4><ul><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='green'>+6.3%</font>) shares push higher following reports that claims related to northern California wildfires in 2017-18 will be <a href=\"https://www.reuters.com/article/us-pg-e-us-bankruptcy/wildfire-victims-in-pge-bankruptcy-see-13-5-billion-in-claims-idUSKBN1WM23A\" target=\"_blank\">capped at $13.5B</a>.</li><li>A lawyer for the committee representing wildfire victims in the PG&amp;E bankruptcy case reportedly said at a hearing today that the committee sees $13.5B as the utility's cost for paying claims of the victims.</li><li>PG&amp;E already has reached settlements worth a combined $12B to resolve claims of a group of public entities hit by the fires and insurers who had made payments for wildfire-related claims.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504305\" data-linked=\"PG&amp;E wildfire victims reportedly to see $13.5B in claims\" data-tweet=\"$PCG - PG&amp;E wildfire victims reportedly to see $13.5B in claims https://seekingalpha.com/news/3504305-pg-and-e-wildfire-victims-reportedly-to-see-13_5b-in-claims?source=tweet\" data-url=\"https://seekingalpha.com/news/3504305-pg-and-e-wildfire-victims-reportedly-to-see-13_5b-in-claims\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504302\" data-ts=\"1570476262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRNE\" target=\"_blank\">SRNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504302-sorrento-down-22-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sorrento down 22% on equity offering</a></h4><ul><li>Sorrento Therapeutics (<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color=\"red\">-21.8%</font>) has <a href=\"https://seekingalpha.com/pr/17655286-sorrento-therapeutics-announces-25-million-registered-direct-offering\" target=\"_blank\">agreed to sell</a> ~10.9M common shares and warrants to purchase up to the same number of shares at $2.40 for $2.30 per share and accompanying warrant in a direct offering to institutional investors.</li><li>Gross proceeds should be ~$25M. Closing date is October 9.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504302\" data-linked=\"Sorrento down 22% on equity offering\" data-tweet=\"$SRNE - Sorrento down 22% on equity offering https://seekingalpha.com/news/3504302-sorrento-down-22-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3504302-sorrento-down-22-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504300\" data-ts=\"1570475688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504300-stocks-swing-down-china-says-ip-is-off-table\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks swing down as China says IP is off the table</a></h4><ul><li>Any gains that stocks made in the early afternoon backtrack after Fox Business's Edward Lawrence follows up his earlier tweet that the Chinese are willing to make a trade deal with the U.S. on parts that they've already agreed upon.</li><li>The <a href=\"https://twitter.com/NewsEdward/status/1181269157024800769\" target=\"_blank\">second tweet</a> said the Chinese Commerce Ministry will never agree to \"changes to their laws to protect intellectual property.\"</li><li>The Chinese ministry says they'll deal with IP theft through administrative regulations.</li><li>The Nasdaq <font color=\"red\">slips 0.1%</font>, while the S&amp;P 500 and the Dow <font color=\"red\">lose 0.2%</font>.</li><li>Early in the session, stocks were weak after Chinese officials signaled that they're<a href=\"https://www.bloomberg.com/news/articles/2019-10-06/china-narrows-scope-for-trade-deal-with-u-s-ahead-of-talks\" target=\"_blank\"> reluctant</a> to reach a broad trade deal with President Trump, according to a Bloomberg News report.</li><li>All but two of the 11 S&amp;P 500 industry sectors are in the red, with consumer staples (<font color=\"red\">-0.6%</font>) and energy (<font color=\"red\">-0.4%</font>) falling the most; communication services (<font color=\"green\">+0.3%</font>) and materials (<font color=\"green\">+0.1%</font>) are the only sectors registering gains.</li><li>10-year Treasury is still down, lifting yield 3 basis points to 1.557%.</li><li>U.S. Dollar Index <font color=\"green\">rises 0.2%</font> to 98.96.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504300\" data-linked=\"Stocks swing down as China says IP is off the table\" data-tweet=\"Stocks swing down as China says IP is off the table https://seekingalpha.com/news/3504300-stocks-swing-down-china-says-ip-is-off-table?source=tweet\" data-url=\"https://seekingalpha.com/news/3504300-stocks-swing-down-china-says-ip-is-off-table\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>204&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504297\" data-ts=\"1570474890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504297-crwd-maxr-and-cnsl-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CRWD, MAXR and CNSL among tech movers</a></h4><ul><li><strong>Gainers: </strong>One Stop Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/OSS' title='One Stop Systems, Inc.'>OSS</a>) <font color=\"green\">+13%</font>. Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc.'>MAXR</a>) <font color=\"green\">+8%</font>. Aehr Test Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/AEHR' title='Aehr Test Systems'>AEHR</a>) <font color=\"green\">+8%</font>. CrowdStrike Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CRWD' title='CrowdStrike Holdings, Inc.'>CRWD</a>) <font color=\"green\">+8%</font>. Amtech Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a>) <font color=\"green\">+7%</font>.</li> <li><strong>Losers: </strong>DPW Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <font color=\"red\">-11%</font>. IDT Corporation (NYSE:<a href='https://seekingalpha.com/symbol/IDT' title='IDT Corporation'>IDT</a>) <font color=\"red\">-8%</font>. Exela Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/XELA' title='Exela Technologies, Inc.'>XELA</a>) <font color=\"red\">-7%</font>. Consolidated Communications Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CNSL' title='Consolidated Communications Holdings, Inc.'>CNSL</a>) <font color=\"red\">-6%</font>. Verb Technology Company (NASDAQ:<a href='https://seekingalpha.com/symbol/VERB' title='Verb Technology Company, Inc.'>VERB</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504297\" data-linked=\"CRWD, MAXR and CNSL among tech movers\" data-tweet=\"$OSS $MAXR $AEHR - CRWD, MAXR and CNSL among tech movers https://seekingalpha.com/news/3504297-crwd-maxr-and-cnsl-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3504297-crwd-maxr-and-cnsl-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504294\" data-ts=\"1570474277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504294-brazil-telecom-rivals-talking-over-oi-buyout-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil telecom rivals talking over Oi buyout - report</a></h4><ul>   <li>Telefonica (<a href=\"http://seekingalpha.com/symbol/TEF\" target=\"_blank\">TEF</a> <font color=\"green\">+0.5%</font>) is negotiating with rivals Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TIAJF\" target=\"_blank\">TIAJF</a> <font color=\"red\">-1.8%</font>) and América Móvil (<a href=\"http://seekingalpha.com/symbol/AMX\" target=\"_blank\">AMX</a> <font color=\"red\">-1.1%</font>) to arrange to buy struggling Oi (OIBR.C <font color=\"red\">-3.5%</font>), according to a report in <i>Expansion.</i></li>    <li>They would buy the company (responsible for Brazil's largest-ever bankruptcy) together and then split the assets, according to the report.</li>    <li>América Móvil <a href=\"https://www.reuters.com/article/us-oi-sa-m-a/america-movil-says-not-negotiating-with-telefonica-telecom-italia-over-oi-idUSKBN1WM1FY\" target=\"_blank\">says in response</a> that it's not negotiating a joint bid with its competitors -- \"Absolutely nothing has been negotiated\" -- but won't rule out such a deal.</li>    <li>The company's Arturo Elias Ayub says the company would need to make a careful analysis of Oi's assets in terms of prices and locations before making such a bid.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3504294\" data-linked=\"Brazil telecom rivals talking over Oi buyout - report\" data-tweet=\"$TEF $TIAJF $AMX - Brazil telecom rivals talking over Oi buyout - report https://seekingalpha.com/news/3504294-brazil-telecom-rivals-talking-over-oi-buyout-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3504294-brazil-telecom-rivals-talking-over-oi-buyout-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504289\" data-ts=\"1570471559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504289-gold-resource-leads-energy-materials-gainers-contango-oil-gas-and-china-natural-resources\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold Resource leads Energy/Materials gainers; Contango Oil &amp; Gas and China Natural Resources among losers</a></h4><ul><li><b>Gainers:</b> Gold Resource (NYSEMKT:<a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a>) <font color=\"green\">+8%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"green\">+8%</font>. McDermott International (NYSE:<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a>) <font color=\"green\">+8%</font>. HighPoint Resources (NYSE:<a href='https://seekingalpha.com/symbol/HPR' title='HighPoint Resources Corporation'>HPR</a>) <font color=\"green\">+7%</font>. CARBO Ceramics (NYSE:<a href='https://seekingalpha.com/symbol/CRR' title='CARBO Ceramics Inc.'>CRR</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers:</b> Contango Oil &amp; Gas (NYSEMKT:<a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a>) <font color=\"red\">-8%</font>. BP Prudhoe Bay Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/BPT' title='BP Prudhoe Bay Royalty Trust'>BPT</a>) <font color=\"red\">-7%</font>. China Natural Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504289\" data-linked=\"Gold Resource leads Energy/Materials gainers; Contango Oil &amp; Gas and China Natural Resources among losers\" data-tweet=\"$GORO $TUSK $MDR - Gold Resource leads Energy/Materials gainers; Contango Oil &amp; Gas and China Natural Resources among losers https://seekingalpha.com/news/3504289-gold-resource-leads-energy-materials-gainers-contango-oil-gas-and-china-natural-resources?source=tweet\" data-url=\"https://seekingalpha.com/news/3504289-gold-resource-leads-energy-materials-gainers-contango-oil-gas-and-china-natural-resources\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504288\" data-ts=\"1570471489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504288-overstock-rallies-amid-customer-day-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Overstock rallies amid Customer Day event</a></h4><ul> <li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) is <font color=\"green\">up 8.44%</font> as the company's 36-hour Customer Day event brings attention back to the retail business.</li><li>The sale runs until midnight eastern time tonight.</li> <li>Shares of Overstock are still down almost 50% from where they stood a month ago.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3504288\" data-linked=\"Overstock rallies amid Customer Day event\" data-tweet=\"$OSTK - Overstock rallies amid Customer Day event https://seekingalpha.com/news/3504288-overstock-rallies-amid-customer-day-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3504288-overstock-rallies-amid-customer-day-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504285\" data-ts=\"1570470629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MIK\" target=\"_blank\">MIK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504285-michaels-rallies-after-adding-ups-access-points\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Michaels rallies after adding UPS access points</a></h4><ul><li>The Michaels Companies (<a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies, Inc.'>MIK</a> <font color='green'>+6.1%</font>) announce the complete rollout of UPS Access Point locations to more than 1.1K Michaels Companies stores nationwide.</li><li>The retailer says customers are now able to ship UPS packages directly to a Michaels store, as well as drop off pre-labeled shipments and make returns to e-commerce retailers that offer UPS drop off.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17654514-michaels-customers-can-now-pick-drop-packages-1100-stores-nationwide-ups-access-point\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3504285\" data-linked=\"Michaels rallies after adding UPS access points\" data-tweet=\"$MIK - Michaels rallies after adding UPS access points https://seekingalpha.com/news/3504285-michaels-rallies-after-adding-ups-access-points?source=tweet\" data-url=\"https://seekingalpha.com/news/3504285-michaels-rallies-after-adding-ups-access-points\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504284\" data-ts=\"1570470477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBLU\" target=\"_blank\">JBLU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504284-jetblueplus-2-after-buckingham-research-lift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JetBlue +2% after Buckingham Research lift</a></h4><ul> <li>JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a> <font color='green'>+2.1%</font>) trades higher after Buckingham Research <a href=\"https://twitter.com/BuckResearch/status/1181172881641938945\" target=\"_blank\">upgrades</a> the airline stock to Buy from Neutral.</li> <li>The firm points to attractive valuation on JetBlue  and thinks IT investment will pay off for the airline. Analyst Daniel McKenzie and team <a href=\"https://twitter.com/BuckResearch/status/1181172881641938945\" target=\"_blank\">summarize</a> by noting theat the JBLU self-help story is gaining a key revenue lever.</li> <li>Wall Street analyst <a href=\"https://seekingalpha.com/symbol/JBLU/ratings/sell-side-ratings\" target=\"_blank\">scorecard</a> on JetBlue: 4 Buy-equivalent ratings, 12 Hold-equivalent ratings, 2 Sell-equivalent ratings.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3504284\" data-linked=\"JetBlue +2% after Buckingham Research lift\" data-tweet=\"$JBLU - JetBlue +2% after Buckingham Research lift https://seekingalpha.com/news/3504284-jetblueplus-2-after-buckingham-research-lift?source=tweet\" data-url=\"https://seekingalpha.com/news/3504284-jetblueplus-2-after-buckingham-research-lift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504283\" data-ts=\"1570470393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504283-barclays-sees-beat-and-raise-coming-for-microsoft-techs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays sees beat-and-raise coming for Microsoft, techs</a></h4><ul>   <li>A number of tech stocks are looking ahead to a strong earnings season, Barclays writes, with Microsoft (<a href=\"http://seekingalpha.com/symbol/MSFT\" target=\"_blank\">MSFT</a> <font color=\"red\">-0.1%</font>) looking like the \"cleanest story.\"</li>    <li>The bank's expecting a beat-and-raise from the tech giant, as well as from most of the techs it's highlighting following its recent survey.</li>    <li>Dynatrace (<a href=\"http://seekingalpha.com/symbol/DT\" target=\"_blank\">DT</a> <font color=\"green\">+0.5%</font>) should also see a positive catalyst via beat-and-raise, as should Talend (<a href=\"http://seekingalpha.com/symbol/TLND\" target=\"_blank\">TLND</a> <font color=\"green\">+1.8%</font>), Barclays says -- and a recent sell-off in cybersecurity and software focuses attention on companies with good execution including Mimecast (<a href=\"http://seekingalpha.com/symbol/MIME\" target=\"_blank\">MIME</a> <font color=\"green\">+2.9%</font>) and Fortinet (<a href=\"http://seekingalpha.com/symbol/FTNT\" target=\"_blank\">FTNT</a> <font color=\"green\">+0.9%</font>).</li>    <li>\u201cMarkets are nervous about growth, but our VAR survey results were solid and the set- up for most of our companies suggests another round of beat and raise numbers,\" Barclays says.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3504283\" data-linked=\"Barclays sees beat-and-raise coming for Microsoft, techs\" data-tweet=\"$MSFT $DT $TLND - Barclays sees beat-and-raise coming for Microsoft, techs https://seekingalpha.com/news/3504283-barclays-sees-beat-and-raise-coming-for-microsoft-techs?source=tweet\" data-url=\"https://seekingalpha.com/news/3504283-barclays-sees-beat-and-raise-coming-for-microsoft-techs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504275\" data-ts=\"1570468237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRQR\" target=\"_blank\">PRQR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504275-proqr-up-1-ahead-of-sepofarsen-data-readout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ProQR up 1% ahead of sepofarsen data readout</a></h4><ul><li>Thinly traded micro cap ProQR Therapeutics N.V. (<a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics N.V.'>PRQR</a> <font color=\"green\">+0.8%</font>) perks up, albeit on below-average volume, ahead of its <a href=\"https://seekingalpha.com/pr/17654424-proqr-present-top-line-results-phase-1-2-study-sepofarsen-lca10-patients-ahead-aao\" target=\"_blank\">release of topline results</a> from a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03140969?lead=proqr+therapeutics&amp;rank=4\" target=\"_blank\">PQ-110-001</a>, evaluating lead candidate sepofarsen (QR-110) in pediatric patients with <a href=\"https://ghr.nlm.nih.gov/condition/leber-congenital-amaurosis\" target=\"_blank\">Leber congenital amaurosis</a> type 10 (LCA10), an inherited disorder characterized by progressive vision loss early in life.</li><li>The data will be presented at the American Academy of Ophthalmology Annual Meeting in San Francisco on October 10. The company will host a conference call at 8:00 am ET that day to discuss the results in detail.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504275\" data-linked=\"ProQR up 1% ahead of sepofarsen data readout\" data-tweet=\"$PRQR - ProQR up 1% ahead of sepofarsen data readout https://seekingalpha.com/news/3504275-proqr-up-1-ahead-of-sepofarsen-data-readout?source=tweet\" data-url=\"https://seekingalpha.com/news/3504275-proqr-up-1-ahead-of-sepofarsen-data-readout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504274\" data-ts=\"1570467650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504274-cemtrex-and-ampco-pittsburgh-in-industrial-gainers-pioneer-power-solutions-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cemtrex and Ampco-Pittsburgh in industrial gainers; Pioneer Power Solutions leads losers</a></h4><ul><li><b>Gainers: </b>Cemtrex (NASDAQ:<a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a>) <font color=\"green\">+5%</font>. Ampco-Pittsburgh (NYSE:<a href='https://seekingalpha.com/symbol/AP' title='Ampco-Pittsburgh Corporation'>AP</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Pioneer Power Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/PPSI' title='Pioneer Power Solutions, Inc.'>PPSI</a>) <font color=\"red\">-10%</font>. Perma-Fix Environmental Services (NASDAQ:<a href='https://seekingalpha.com/symbol/PESI' title='Perma-Fix Environmental Services, Inc.'>PESI</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504274\" data-linked=\"Cemtrex and Ampco-Pittsburgh in industrial gainers; Pioneer Power Solutions leads losers\" data-tweet=\"$CETX $AP $PPSI - Cemtrex and Ampco-Pittsburgh in industrial gainers; Pioneer Power Solutions leads losers https://seekingalpha.com/news/3504274-cemtrex-and-ampco-pittsburgh-in-industrial-gainers-pioneer-power-solutions-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3504274-cemtrex-and-ampco-pittsburgh-in-industrial-gainers-pioneer-power-solutions-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504273\" data-ts=\"1570467176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504273-triple-s-management-and-hennessy-advisors-among-financial-gainers-jefferies-financial-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Triple-S Management and Hennessy Advisors among financial gainers, Jefferies Financial Group the only loser</a></h4><ul><li><b>Gainers:</b> OptimumBank Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OPHC' title='OptimumBank Holdings, Inc.'>OPHC</a>) <font color=\"green\">+10%</font>. Triple-S Management (NYSE:<a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a>) <font color=\"green\">+8%</font>. Hennessy Advisors (NASDAQ:<a href='https://seekingalpha.com/symbol/HNNA' title='Hennessy Advisors, Inc.'>HNNA</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers:</b> Jefferies Financial Group (NYSE:<a href='https://seekingalpha.com/symbol/JEF' title='Jefferies Financial Group Inc.'>JEF</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504273\" data-linked=\"Triple-S Management and Hennessy Advisors among financial gainers, Jefferies Financial Group the only loser\" data-tweet=\"$OPHC $GTS $HNNA - Triple-S Management and Hennessy Advisors among financial gainers, Jefferies Financial Group the only loser https://seekingalpha.com/news/3504273-triple-s-management-and-hennessy-advisors-among-financial-gainers-jefferies-financial-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3504273-triple-s-management-and-hennessy-advisors-among-financial-gainers-jefferies-financial-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504271\" data-ts=\"1570466974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCLI\" target=\"_blank\">BCLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504271-brainstorm-up-1-on-u-s-patent-covering-nurown\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brainstorm up 1% on U.S. patent covering NurOwn</a></h4><ul><li>Thinly traded nano cap BrainStorm Cell Therapeutics (<a href='https://seekingalpha.com/symbol/BCLI' title='Brainstorm Cell Therapeutics Inc.'>BCLI</a> <font color=\"green\">+1.4%</font>) is up on below-average volume in reaction to the issuance of a <a href=\"https://seekingalpha.com/pr/17654605-brainstorm-announces-notice-us-patent-allowance-nurown-cellular-therapeutic-technology\" target=\"_blank\">new U.S. patent</a> covering its NurOwn cell therapy.</li><li>The patent, entitled \"Method of Qualifying Cells,\" covers a pharmaceutical composition for MSC-NTF cells secreting neurotrophic factors (NurOwn) consisting of a culture medium as a carrier and an isolated population of differentiated bone marrow-derived mesenchymal stem cells (MSCs) that secrete neurotrophic factors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504271\" data-linked=\"Brainstorm up 1% on U.S. patent covering NurOwn\" data-tweet=\"$BCLI - Brainstorm up 1% on U.S. patent covering NurOwn https://seekingalpha.com/news/3504271-brainstorm-up-1-on-u-s-patent-covering-nurown?source=tweet\" data-url=\"https://seekingalpha.com/news/3504271-brainstorm-up-1-on-u-s-patent-covering-nurown\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504269\" data-ts=\"1570466603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAT\" target=\"_blank\">NAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504269-tanker-shipping-stocks-up-sharply-industry-rates-continue-to-climb\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tanker, shipping stocks up sharply as industry rates continue to climb</a></h4><ul><li>Tanker and shipping stocks are on the move after Suezmax  rates jumped 60% last Friday and soared 400% in a month and the Clarkson Platou international shipbroking firm reported the <a href=\"https://seekingalpha.com/pr/17654604-nordic-american-tankers-ltd-nyse-nat-exceptionally-strong-tanker-market-nat-benefitting\" target=\"_blank\">largest week-on-week increase</a> in the history of  its freight index.</li><li>According to Nordic American Tankers (<a href='https://seekingalpha.com/symbol/NAT' title='Nordic American Tankers Limited'>NAT</a> <font color=\"green\">+11.5%</font>), the Suezmax spot market is reported to ~$68K/day and rising; the company's says its operating costs are only ~$8K/day.</li><li>NAT says it is \"in a very strong position with 21 of our 23 Suezmaxes in the spot market,\" while noting Q3 results will change little vs. Q2 as the upturn from the past three weeks will filter  through to Q4 results.</li><li>Also, S&amp;P Global Platts reports Asian dirty tanker rates on most vessel sizes for Persian Gulf loading  rose by the most in any single day YTD to 11-year highs, as U.S. sanctions on China's Cosco Shipping squeeze supply and push up rates.</li><li>Reuters reports Occidental Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/OXY' title='Occidental Petroleum Corporation'>OXY</a>) provisionally chartered the very large crude carrier <em>Maran Andromeda</em> to ship U.S. crude to South Korea for a <a href=\"https://www.reuters.com/article/us-occidental-crude-shipping/occidental-tentatively-books-oil-supertanker-for-record-13-25-million-to-asia-idUSKBN1WM205\" target=\"_blank\">new record of $13.25M</a> next month.</li><li>Other big gainers in the group include <a href='https://seekingalpha.com/symbol/TNK' title='Teekay Tankers Ltd.'>TNK</a> <font color=\"green\">+10.8%</font>, <a href='https://seekingalpha.com/symbol/NNA' title='Navios Maritime Acquisition Corporation'>NNA</a> <font color=\"green\">+9.5%</font>, <a href='https://seekingalpha.com/symbol/TNP' title='Tsakos Energy Navigation Limited'>TNP</a> <font color=\"green\">+8.1%</font>, <a href='https://seekingalpha.com/symbol/TK' title='Teekay Corporation'>TK</a> <font color=\"green\">+7.7%</font>, <a href='https://seekingalpha.com/symbol/DSSI' title='Diamond S Shipping Inc.'>DSSI</a> <font color=\"green\">+6.9%</font>, <a href='https://seekingalpha.com/symbol/ASC' title='Ardmore Shipping Corporation'>ASC</a> <font color=\"green\">+5.8%</font>, <a href='https://seekingalpha.com/symbol/GLOG' title='GasLog Ltd.'>GLOG</a> <font color=\"green\">+5.7%</font>, <a href='https://seekingalpha.com/symbol/FRO' title='Frontline Ltd.'>FRO</a> <font color=\"green\">+5.3%</font>, <a href='https://seekingalpha.com/symbol/DHT' title='DHT Holdings, Inc.'>DHT</a> <font color=\"green\">+4.6%</font>, <a href='https://seekingalpha.com/symbol/EURN' title='Euronav NV'>EURN</a> <font color=\"green\">+4.3%</font>, <a href='https://seekingalpha.com/symbol/SB' title='Safe Bulkers, Inc.'>SB</a> <font color=\"green\">+3.6%</font>, <a href='https://seekingalpha.com/symbol/GLOP' title='GasLog Partners LP'>GLOP</a> <font color=\"green\">+2.7%</font>, <a href='https://seekingalpha.com/symbol/GNK' title='Genco Shipping & Trading Limited'>GNK</a> <font color=\"green\">+2.4%</font>, <a href='https://seekingalpha.com/symbol/CPLP' title='Capital Product Partners L.P.'>CPLP</a> <font color=\"green\">+2.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504269\" data-linked=\"Tanker, shipping stocks up sharply as industry rates continue to climb\" data-tweet=\"$NAT $TNK $TNP - Tanker, shipping stocks up sharply as industry rates continue to climb https://seekingalpha.com/news/3504269-tanker-shipping-stocks-up-sharply-industry-rates-continue-to-climb?source=tweet\" data-url=\"https://seekingalpha.com/news/3504269-tanker-shipping-stocks-up-sharply-industry-rates-continue-to-climb\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>117&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504268\" data-ts=\"1570465997\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504268-healthcare-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare dominate midday movers</a></h4><ul><li><strong>Gainers: </strong>Akcea Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics, Inc.'>AKCA</a>) <font color=\"green\">+29%</font>. Liquid Media Group (NASDAQ:<a href='https://seekingalpha.com/symbol/YVR' title='Liquid Media Group Ltd.'>YVR</a>) <font color=\"green\">+24%</font>. AgeX Therapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/AGE' title='AgeX Therapeutics, Inc.'>AGE</a>) <font color=\"green\">+20%</font>. Sutro Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/STRO' title='Sutro Biopharma, Inc.'>STRO</a>) <font color=\"green\">+19%</font>. Livongo Health (NASDAQ:<a href='https://seekingalpha.com/symbol/LVGO' title='Livongo Health, Inc.'>LVGO</a>) <font color=\"green\">+15%</font>. Motus GI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings, Inc.'>MOTS</a>) <font color=\"green\">+12%</font>. Teekay Tankers (NYSE:<a href='https://seekingalpha.com/symbol/TNK' title='Teekay Tankers Ltd.'>TNK</a>) <font color=\"green\">+11%</font>. Nordic American Tankers (NYSE:<a href='https://seekingalpha.com/symbol/NAT' title='Nordic American Tankers Limited'>NAT</a>) <font color=\"green\">+11%</font>. One Stop Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/OSS' title='One Stop Systems, Inc.'>OSS</a>) <font color=\"green\">+11%</font>. OptimumBank Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OPHC' title='OptimumBank Holdings, Inc.'>OPHC</a>) <font color=\"green\">+10%</font>.</li> <li><strong>Losers: </strong>NGM Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/NGM' title='NGM Biopharmaceuticals, Inc.'>NGM</a>) <font color=\"red\">-15%</font>. Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"red\">-12%</font>. Pioneer Power Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/PPSI' title='Pioneer Power Solutions, Inc.'>PPSI</a>) <font color=\"red\">-12%</font>. Intersect ENT (NASDAQ:<a href='https://seekingalpha.com/symbol/XENT' title='Intersect ENT, Inc.'>XENT</a>) <font color=\"red\">-11%</font>. TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"red\">-10%</font>. DiaMedica Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/DMAC' title='DiaMedica Therapeutics Inc.'>DMAC</a>) <font color=\"red\">-10%</font>. Adaptimmune Therapeutics plc (NASDAQ:<a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a>) <font color=\"red\">-10%</font>. LiveXLive Media (NASDAQ:<a href='https://seekingalpha.com/symbol/LIVX' title='LiveXLive Media, Inc.'>LIVX</a>) <font color=\"red\">-9%</font>. Civeo Corporation (NYSE:<a href='https://seekingalpha.com/symbol/CVEO' title='Civeo Corporation'>CVEO</a>) <font color=\"red\">-8%</font>. Eloxx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ELOX' title='Eloxx Pharmaceuticals, Inc.'>ELOX</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504268\" data-linked=\"Healthcare dominate midday movers\" data-tweet=\"$AKCA $YVR $AGE - Healthcare dominate midday movers https://seekingalpha.com/news/3504268-healthcare-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3504268-healthcare-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504260\" data-ts=\"1570464386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STRO\" target=\"_blank\">STRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504260-sutro-bio-up-22-after-mixed-shelf-filing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sutro Bio up 22% after mixed shelf filing</a></h4><ul><li>Thinly traded micro cap Sutro Biopharma (<a href='https://seekingalpha.com/symbol/STRO' title='Sutro Biopharma, Inc.'>STRO</a> <font color=\"green\">+22.3%</font>) is up on below-average volume, a scant 25K shares, on the heels of its <a href=\"https://www.sec.gov/Archives/edgar/data/1382101/000119312519262726/d813273ds3.htm\" target=\"_blank\">prospectus</a> for a $250M mixed shelf offering filed on Friday, October 4, after the close.</li><li>On the working capital front, at the end of June, it had $153M in quick assets while operations consumed ~$36M in H1 so it is not under near-term pressure for additional funds.</li><li>In a <a href=\"https://seekingalpha.com/article/4240314-sutro-biopharma-stro-presents-bio-ceo-and-investor-conference-slideshow\" target=\"_blank\">presentation</a> earlier this year, CEO Bill Newell stated that the company's cash runway should extend into 2021 (slide #4).</li></ul><div class=\"tiny-share-widget\" data-id=\"3504260\" data-linked=\"Sutro Bio up 22% after mixed shelf filing\" data-tweet=\"$STRO - Sutro Bio up 22% after mixed shelf filing https://seekingalpha.com/news/3504260-sutro-bio-up-22-after-mixed-shelf-filing?source=tweet\" data-url=\"https://seekingalpha.com/news/3504260-sutro-bio-up-22-after-mixed-shelf-filing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504259\" data-ts=\"1570464130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504259-dean-foods-and-vuzix-in-consumer-gainers-nio-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dean Foods and Vuzix in consumer gainers; NIO among the losers</a></h4><ul><li><b>Gainers: </b>Dean Foods (NYSE:<a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a>) <font color=\"green\">+9%</font>. Vuzix (NASDAQ:<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corporation'>VUZI</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"red\">-11%</font>. Lifetime Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/LCUT' title='Lifetime Brands, Inc.'>LCUT</a>) <font color=\"red\">-6%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Inc.'>NIO</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504259\" data-linked=\"Dean Foods and Vuzix in consumer gainers; NIO among the losers\" data-tweet=\"$DF $VUZI $PETZ - Dean Foods and Vuzix in consumer gainers; NIO among the losers https://seekingalpha.com/news/3504259-dean-foods-and-vuzix-in-consumer-gainers-nio-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3504259-dean-foods-and-vuzix-in-consumer-gainers-nio-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504256\" data-ts=\"1570463813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPR\" target=\"_blank\">HPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504256-highpoint-resources-sees-q3-production-high-end-of-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HighPoint Resources sees Q3 production at high end of guidance</a></h4><ul><li>HighPoint Resources (<a href='https://seekingalpha.com/symbol/HPR' title='HighPoint Resources Corporation'>HPR</a> <font color='green'>+9.5%</font>) says it <a href=\"https://seekingalpha.com/pr/17654361-highpoint-resources-provides-operations-update-including-positive-hereford-field-results\" target=\"_blank\">expects Q3 sales volume will increase 20% Q/Q</a> to 3.4M boe, at the high end of the company's 3.3M-3.4M boe guidance despite depressed processing yields.</li><li>HPR sees Q3 oil production volumes rising by 25% Q/Q to 2.18M barrels, or 64% of total equivalent production sales volume.</li><li>Additionally, the company says it achieved strong operating results from its Hereford field, with wells in DSU 11-63-16 exhibiting a 75% current daily production increase over previously completed wells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504256\" data-linked=\"HighPoint Resources sees Q3 production at high end of guidance\" data-tweet=\"$HPR - HighPoint Resources sees Q3 production at high end of guidance https://seekingalpha.com/news/3504256-highpoint-resources-sees-q3-production-high-end-of-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3504256-highpoint-resources-sees-q3-production-high-end-of-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504248\" data-ts=\"1570463076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTTR\" target=\"_blank\">RTTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504248-ritter-pharma-to-explore-strategic-alternatives-shares-ahead-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ritter Pharma to explore strategic alternatives; shares  ahead 20%</a></h4><ul><li>Nano cap Ritter Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals, Inc.'>RTTR</a> <font color=\"green\">+20.3%</font>) is up on almost a 4x surge in volume on the heels of its <a href=\"https://seekingalpha.com/pr/17654848-ritter-pharmaceuticals-engages-financial-advisor-explore-strategic-alternatives\" target=\"_blank\">announcement </a>it has engaged A.G.P./Alliance Global Partners to advise it on strategic alternatives aimed at boosting shareholder value.</li><li>Management will provide additional updates when appropriate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504248\" data-linked=\"Ritter Pharma to explore strategic alternatives; shares  ahead 20%\" data-tweet=\"$RTTR - Ritter Pharma to explore strategic alternatives; shares ahead 20% https://seekingalpha.com/news/3504248-ritter-pharma-to-explore-strategic-alternatives-shares-ahead-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3504248-ritter-pharma-to-explore-strategic-alternatives-shares-ahead-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504247\" data-ts=\"1570462586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HL\" target=\"_blank\">HL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504247-hecla-minings-q3-silver-output-rises-31\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hecla Mining&#39;s Q3 silver output rises 31%</a></h4><ul><li>Hecla Mining (<a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Company'>HL</a> <font color='green'>+2.1%</font>) moves higher after reporting Q3 silver production <a href=\"https://seekingalpha.com/pr/17654335-hecla-reports-30-percent-increase-third-quarter-silver-production\" target=\"_blank\">rose 31% Y/Y</a> to 3.29M oz. and gold production climbed 6% to 77.3K oz.</li><li>Q3 silver production from HL's Greens Creek mine in Alaska jumped by nearly 700K oz., or 36% Y/Y, to 2.54M oz., and the mill operated at an average of 2,321 tons/day; on a percentage basis, the largest increase was seen at the Lucky Friday mine in Idaho, where output surged 266% Y/Y to 115.7K oz.</li><li>HL says cash holdings increased by $24M to $33M during the quarter, as it expected that \"dialing back our expenditures while achieving our expected  production and sales targets would increase our cash flow generation,\" adding it expects more of the same in Q4.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504247\" data-linked=\"Hecla Mining&#39;s Q3 silver output rises 31%\" data-tweet=\"$HL - Hecla Mining&#39;s Q3 silver output rises 31% https://seekingalpha.com/news/3504247-hecla-minings-q3-silver-output-rises-31?source=tweet\" data-url=\"https://seekingalpha.com/news/3504247-hecla-minings-q3-silver-output-rises-31\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504245\" data-ts=\"1570462409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIM\" target=\"_blank\">AIM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504245-aim-immunotech-up-12-on-trial-update-improved-cash-position\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AIM ImmunoTech up 12% on trial update, improved cash position</a></h4><ul><li>Nano cap AIM ImmunoTech (<a href='https://seekingalpha.com/symbol/AIM' title='AIM ImmunoTech Inc.'>AIM</a> <font color=\"green\">+11.6%</font>) is up on below-average volume following its <a href=\"https://seekingalpha.com/pr/17654345-aim-immunotech-provides-comprehensive-clinical-trials-update-major-inflection-points\" target=\"_blank\">announcement </a>that it ended Q3 with ~$12.5M in cash, sufficient resources, it says, to support its ongoing operations leading up to two key data readouts.</li><li>Results from a Phase 2 study assessing Ampligen, combined with Merck's Keytruda (pembrolizumab), in metastatic triple-negative breast cancer may be available as soon as six months hence.</li><li>Results from another Phase 2, evaluating the same combination in advanced recurrent ovarian cancer, may be available in 12 months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504245\" data-linked=\"AIM ImmunoTech up 12% on trial update, improved cash position\" data-tweet=\"$AIM - AIM ImmunoTech up 12% on trial update, improved cash position https://seekingalpha.com/news/3504245-aim-immunotech-up-12-on-trial-update-improved-cash-position?source=tweet\" data-url=\"https://seekingalpha.com/news/3504245-aim-immunotech-up-12-on-trial-update-improved-cash-position\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504244\" data-ts=\"1570461876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNNA\" target=\"_blank\">SNNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504244-sienna-files-u-s-application-for-snaminus-001-for-light-hair-removal-shares-up-23\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sienna files U.S. application for SNA-001 for light hair removal; shares up 23%</a></h4><ul><li>Sienna Biopharmaceuticals (<a href='https://seekingalpha.com/symbol/SNNA' title='Sienna Biopharmaceuticals, Inc.'>SNNA</a> <font color=\"green\">+22.8%</font>) has <a href=\"https://seekingalpha.com/pr/17654677-sienna-biopharmaceuticals-files-510-k-submission-fda-snaminus-001-novel-silver-photoparticle\" target=\"_blank\">filed a 510(k) application</a> with the FDA for SNA-001 as a topical pretreatment to standard laser devices to remove unwanted light hair. Specifically, the company seeks clearance to use SNA-001, in conjunction with an 810 nm diode laser, for the removal of unwanted white, gray light red and light brown hair in women and men.</li><li>Hair removal by laser has been in use by almost 25 years in the U.S. SNA-001 contains silver particles which harness a laser's light energy to thermally target the structural unit of the hair follicle.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504244\" data-linked=\"Sienna files U.S. application for SNA-001 for light hair removal; shares up 23%\" data-tweet=\"$SNNA - Sienna files U.S. application for SNA-001 for light hair removal; shares up 23% https://seekingalpha.com/news/3504244-sienna-files-u-s-application-for-snaminus-001-for-light-hair-removal-shares-up-23?source=tweet\" data-url=\"https://seekingalpha.com/news/3504244-sienna-files-u-s-application-for-snaminus-001-for-light-hair-removal-shares-up-23\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504243\" data-ts=\"1570461582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAXR\" target=\"_blank\">MAXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504243-maxarplus-5_6-after-air-force-architecture-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxar +5.6% after Air Force architecture deal</a></h4><ul>   <li>Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc.'>MAXR</a>) is <font color=\"green\">up 5.6%</font> today after its win of a <a href=\"https://seekingalpha.com/pr/17654295-maxar-selected-develop-automated-cloud-based-geoint-analysis-architecture-u-s-air-force\" target=\"_blank\">$14.2M deal</a> to build a cloud-based geospatial intelligence analysis architecture for the Air Force Research Laboratory.</li>    <li>The Red Wing architecture \"will help to rapidly equip the warfighter with actionable insights to solve dynamic and complex intelligence problems at scale,\" says Maxar's Tony Frazier.</li>    <li>It will provide a more automated approach to dealing with rapidly increasing volumes of data, and expand the use of Amazon managed services in order to increase security and resiliency while pressing costs lower.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3504243\" data-linked=\"Maxar +5.6% after Air Force architecture deal\" data-tweet=\"$MAXR - Maxar +5.6% after Air Force architecture deal https://seekingalpha.com/news/3504243-maxarplus-5_6-after-air-force-architecture-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3504243-maxarplus-5_6-after-air-force-architecture-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504235\" data-ts=\"1570460859\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VVUS\" target=\"_blank\">VVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504235-vivus-up-4-on-advancement-of-qsymia-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivus up 4% on advancement of Qsymia in Europe</a></h4><ul><li>Thinly traded nano cap VIVUS (<a href='https://seekingalpha.com/symbol/VVUS' title='VIVUS, Inc.'>VVUS</a> <font color=\"green\">+4.3%</font>) is up, albeit on very light volume, on the heels of its <a href=\"https://seekingalpha.com/pr/17654459-vivus-announces-acceptance-qsymia-decentralized-marketing-authorization-application-europe\" target=\"_blank\">announcement </a>that that its marketing application in Europe seeking approval of Qsymia (phentermine and topiramate extended-release) has been accepted for review by lead member state Sweden. If approved, the weight loss med will be authorized for sale throughout the EU as early as H2 2020 under its decentralized procedure.</li><li>The FDA approved it in July 2012.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504235\" data-linked=\"Vivus up 4% on advancement of Qsymia in Europe\" data-tweet=\"$VVUS - Vivus up 4% on advancement of Qsymia in Europe https://seekingalpha.com/news/3504235-vivus-up-4-on-advancement-of-qsymia-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3504235-vivus-up-4-on-advancement-of-qsymia-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504233\" data-ts=\"1570460764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504233-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Akcea Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics, Inc.'>AKCA</a>) <font color=\"green\">+38%</font>. Livongo Health (NASDAQ:<a href='https://seekingalpha.com/symbol/LVGO' title='Livongo Health, Inc.'>LVGO</a>) <font color=\"green\">+12%</font>. Motus GI (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings, Inc.'>MOTS</a>) <font color=\"green\">+11%</font>. InfuSystem (NYSEMKT:<a href='https://seekingalpha.com/symbol/INFU' title='InfuSystem Holdings Inc.'>INFU</a>) <font color=\"green\">+10%</font>. Galectin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>NGM Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/NGM' title='NGM Biopharmaceuticals, Inc.'>NGM</a>) <font color=\"red\">-15%</font>. Intersect ENT (NASDAQ:<a href='https://seekingalpha.com/symbol/XENT' title='Intersect ENT, Inc.'>XENT</a>) <font color=\"red\">-11%</font>. Zosano Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma Corporation'>ZSAN</a>) <font color=\"red\">-7%</font>. Spring Bank Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SBPH' title='Spring Bank Pharmaceuticals, Inc.'>SBPH</a>) <font color=\"red\">-7%</font>. Avadel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVDL' title='Avadel Pharmaceuticals plc'>AVDL</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504233\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$AKCA $LVGO $MOTS - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3504233-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3504233-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504226\" data-ts=\"1570459613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPLD\" target=\"_blank\">UPLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504226-uplandplus-3-on-altify-acquisition-and-guidance-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Upland +3% on Altify acquisition and guidance raise</a></h4><ul><li>Upland Software (<a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software, Inc.'>UPLD</a> <font color=\"green\">+3.1%</font>) has <a href=\"https://seekingalpha.com/pr/17654803-upland-software-acquires-altify-raises-guidance\" target=\"_blank\">acquired</a> Altify, leading customer revenue optimization cloud solution for sales and the extended revenue teams, for purchase price of $84M, in cash.</li><li>The acquisition adds ~$24M in annualized revenues, of which $22M are recurring and will be immediately accretive to Upland's Adjusted EBITDA per share.</li><li>Upland drew $59M on revolving credit facility, taking Upland's gross debt outstanding to $409M, and with ~$56M of cash on-hand, Upland's net debt is now ~$353M.</li><li>Upland updates FY19 guidance to revenue $217.3M-$221.3M, and Adj. EBITDA $80.5M -$82.5M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504226\" data-linked=\"Upland +3% on Altify acquisition and guidance raise\" data-tweet=\"$UPLD - Upland +3% on Altify acquisition and guidance raise https://seekingalpha.com/news/3504226-uplandplus-3-on-altify-acquisition-and-guidance-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3504226-uplandplus-3-on-altify-acquisition-and-guidance-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504217\" data-ts=\"1570457957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRZBY\" target=\"_blank\">CRZBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504217-commerzbankminus-1_8-fitch-shifts-ratings-outlook-to-negative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Commerzbank -1.8% as Fitch shifts ratings outlook to negative</a></h4><ul><li>Commerzbank (<a href='https://seekingalpha.com/symbol/CRZBY' title='Commerzbank AG'>OTCPK:CRZBY</a>) (<a href='https://seekingalpha.com/symbol/CRZBF' title='Commerzbank AG'>OTCPK:CRZBF</a>)<font color=\"red\"> falls 1.8%</font> after Fitch Ratings<a href=\"https://www.fitchratings.com/site/pr/10092109\" target=\"_blank\"> revises </a>the outlook on the German bank's long-term issuer default rating to negative from stable.</li><li>Long-term IDR affirmed at BBB+.</li><li>Short-term IDR affirmed at F1.</li><li>Outlook change reflects Fitch's view that Commerzbank's asset quality, capitalization, and funding and liquidity profile have the capacity to support the bank's ratings through its long restructuring period of weak profitability; also reflects limited margin of safety.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3500787-commerzbank-plans-cutting-headcount-2300\" target=\"_blank\">Commerzbank plans cutting headcount by 2,300</a> (Sept. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3504217\" data-linked=\"Commerzbank -1.8% as Fitch shifts ratings outlook to negative\" data-tweet=\"$CRZBY $CRZBF - Commerzbank -1.8% as Fitch shifts ratings outlook to negative https://seekingalpha.com/news/3504217-commerzbankminus-1_8-fitch-shifts-ratings-outlook-to-negative?source=tweet\" data-url=\"https://seekingalpha.com/news/3504217-commerzbankminus-1_8-fitch-shifts-ratings-outlook-to-negative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504216\" data-ts=\"1570457851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAN\" target=\"_blank\">TAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504216-u-s-ends-tariff-exemption-for-bifacial-solar-panels-fslr-spwr-benefit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. ends tariff exemption for bifacial solar panels; FSLR, SPWR could benefit</a></h4><ul><li>The Trump administration says it <a href=\"https://www.cnbc.com/2019/10/07/us-solar-industry-gets-unlikely-boost-from-the-trump-administration.html\" target=\"_blank\">will impose tariffs</a> on bifacial solar panels (<a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a> <font color='red'>-0.5%</font>) beginning Oct. 28, the U.S. Trade Representative's office <a href=\"https://ustr.gov/sites/default/files/enforcement/201Investigations/Withdrawal_of_Bifacial_Solar_Panels_Exclusion_to_the_Solar_Products_Safeguard_Measure.pdf\" target=\"_blank\">announces</a>, eliminating a loophole granted in June for the product and will be subject to the 25% duties announced on imported equipment in early 2018.</li><li>Bifacial panels are gaining traction since their double-sided nature means they absorb more power and are thus more efficient, but they  are in the early stages of development and a relatively small part of the ecosystem, with Bloomberg estimating the panels <a href=\"https://finance.yahoo.com/news/trump-yanks-exemption-solar-relying-212607327.html\" target=\"_blank\">comprised ~3% of the global market</a> in 2018.</li><li>\"Most investors had expected some form of cap to be put in place and not  an outright reversal of the policy,\" says Cowen analyst Jeffrey Osborne, and Goldman Sachs' Brian Lee warns to \"expect significant volatility across solar equities near-term.\"</li><li>Lee says U.S.-based manufacturers such as First Solar (<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='red'>-1.2%</font>) and SunPower (<a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='red'>-0.3%</font>) will be \"key beneficiaries,\" while Chinese solar players with bifacial capacity expansion plans likely will be \"the most negatively impacted  from this unexpected development.\"</li><li>Chinese names including JinkoSolar (<a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='red'>-0.3%</font>), Canadian Solar (<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-2.2%</font>), ReneSola (<a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd'>SOL</a>) and Yingli Green Energy (<a href='https://seekingalpha.com/symbol/YGEHY' title='Yingli Green Energy Holding Company Limited'>OTCPK:YGEHY</a> <font color='green'>+6.2%</font>) show mixed results in early trade.</li><li>Also: <a href='https://seekingalpha.com/symbol/SEDG' title='SolarEdge Technologies, Inc.'>SEDG</a> <font color=\"red\">-1.5%</font>, <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy, Inc.'>ENPH</a> <font color=\"red\">-1.2%</font>, <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar, Inc.'>VSLR</a> <font color=\"green\">+2.2%</font>, <a href='https://seekingalpha.com/symbol/RUN' title='Sunrun Inc.'>RUN</a> <font color=\"red\">-0.1%.</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3504216\" data-linked=\"U.S. ends tariff exemption for bifacial solar panels; FSLR, SPWR could benefit\" data-tweet=\"$TAN $FSLR $SPWR - U.S. ends tariff exemption for bifacial solar panels; FSLR, SPWR could benefit https://seekingalpha.com/news/3504216-u-s-ends-tariff-exemption-for-bifacial-solar-panels-fslr-spwr-benefit?source=tweet\" data-url=\"https://seekingalpha.com/news/3504216-u-s-ends-tariff-exemption-for-bifacial-solar-panels-fslr-spwr-benefit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504215\" data-ts=\"1570457763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXNX\" target=\"_blank\">AXNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504215-axonics-down-6-on-medtronic-filing-for-new-overactive-bladder-device\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axonics down 6% on Medtronic filing for new overactive bladder device</a></h4><ul><li>Thinly traded Axonics Modulation Technologies (<a href='https://seekingalpha.com/symbol/AXNX' title='Axonics Modulation Technologies, Inc.'>AXNX</a> <font color=\"red\">-6%</font>) slips on below-average volume, a modest 144K shares, in apparent response to Medtronic's <a href=\"https://seekingalpha.com/news/3504167-medtronic-files-u-s-application-neurostimulation-device-incontinence\" target=\"_blank\">U.S. marketing application</a> for its miniaturized InterStim Micro sacral nerve stimulator for the treatment of overactive bladder, urinary urge incontinence, unobstructed urinary retention and fecal incontinence.</li><li>Axonics' rival SNM system is CE Mark'd for overactive bladder, fecal incontinence and urinary retention. It is <a href=\"https://seekingalpha.com/news/3497875-fda-oks-axonics-modulations-r-snm-device-fecal-incontinence\" target=\"_blank\">approved</a> in the U.S. for fecal incontinence. Its application for overactive bladder and urinary incontinence is under FDA review.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504215\" data-linked=\"Axonics down 6% on Medtronic filing for new overactive bladder device\" data-tweet=\"$AXNX - Axonics down 6% on Medtronic filing for new overactive bladder device https://seekingalpha.com/news/3504215-axonics-down-6-on-medtronic-filing-for-new-overactive-bladder-device?source=tweet\" data-url=\"https://seekingalpha.com/news/3504215-axonics-down-6-on-medtronic-filing-for-new-overactive-bladder-device\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504209\" data-ts=\"1570457028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENTG\" target=\"_blank\">ENTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504209-entegrisminus-2_2-after-deutsche-bank-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Entegris -2.2% after Deutsche Bank downgrade</a></h4><ul>   <li>Entegris (NASDAQ:<a href='https://seekingalpha.com/symbol/ENTG' title='Entegris, Inc.'>ENTG</a>) is <font color=\"red\">off 2.2%</font> in early going after downgrade to Hold at Deutsche Bank.</li>    <li>The bank updated its price target higher, however, to $49 from $46, now implying 5.2% upside.</li>    <li>Sell-side analysts rate it <a href=\"https://seekingalpha.com/symbol/ENTG/ratings/sell-side-ratings\" target=\"_blank\">Outpeform on average</a>, and <a href=\"https://seekingalpha.com/symbol/ENTG/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Bullish</a> overall. The stock has a <a href=\"https://seekingalpha.com/symbol/ENTG/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504209\" data-linked=\"Entegris -2.2% after Deutsche Bank downgrade\" data-tweet=\"$ENTG - Entegris -2.2% after Deutsche Bank downgrade https://seekingalpha.com/news/3504209-entegrisminus-2_2-after-deutsche-bank-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3504209-entegrisminus-2_2-after-deutsche-bank-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504200\" data-ts=\"1570455940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACOR\" target=\"_blank\">ACOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504200-supreme-court-declines-to-hear-acorda-appeal-of-adverse-ampyra-patent-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supreme Court declines to hear Acorda appeal of adverse Ampyra patent ruling</a></h4><ul><li>The U.S. Supreme Court has declined to hear an appeal from Acorda Therapeutics (<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a> <font color=\"green\">+1%</font>) aimed at reviving certain patents covering MS med Ampyra (dalfampridine). In September 2018, the U.S. Court of Appeals for the Federal Circuit <a href=\"https://seekingalpha.com/news/3389058-acorda-15-percent-adverse-patent-ruling\" target=\"_blank\">voted 2-1</a> invalidating four of its U.S. patents.</li><li>Sales have plummeted since the launch of generic alternatives.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504200\" data-linked=\"Supreme Court declines to hear Acorda appeal of adverse Ampyra patent ruling\" data-tweet=\"$ACOR - Supreme Court declines to hear Acorda appeal of adverse Ampyra patent ruling https://seekingalpha.com/news/3504200-supreme-court-declines-to-hear-acorda-appeal-of-adverse-ampyra-patent-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/3504200-supreme-court-declines-to-hear-acorda-appeal-of-adverse-ampyra-patent-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504197\" data-ts=\"1570455306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LVGO\" target=\"_blank\">LVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504197-livongo-up-8-on-diabetes-contract-win\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Livongo up 8% on diabetes contract win</a></h4><ul><li>Livongo Health (<a href='https://seekingalpha.com/symbol/LVGO' title='Livongo Health, Inc.'>LVGO</a> <font color=\"green\">+8.3%</font>) is up out of the gate in reaction to the award of a <a href=\"https://seekingalpha.com/pr/17654412-livongo-awarded-diabetes-contract-eligible-population-approximately-5_3-million-beneficiaries\" target=\"_blank\">contract </a>for its Diabetes solution from the Federal Employees Health Benefits Program covering ~5.3M employees, retirees and family members with type 1 or 2 diabetes.</li><li>The two-year agreement, commencing on January 1, 2020, will add ~25K Diabetes Members next year and ~45K in 2021. Additional revenue should be $20M - 25M in 2020 and $30M - 35M the year after.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504197\" data-linked=\"Livongo up 8% on diabetes contract win\" data-tweet=\"$LVGO - Livongo up 8% on diabetes contract win https://seekingalpha.com/news/3504197-livongo-up-8-on-diabetes-contract-win?source=tweet\" data-url=\"https://seekingalpha.com/news/3504197-livongo-up-8-on-diabetes-contract-win\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504192\" data-ts=\"1570454985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504192-ringcentralplus-5_9-jpmorgan-upgrades-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RingCentral +5.9% as JPMorgan upgrades to Overweight</a></h4><ul>   <li>RingCentral (NYSE:<a href='https://seekingalpha.com/symbol/RNG' title='RingCentral, Inc.'>RNG</a>) is <font color=\"green\">up 5.9%</font> premarket after a boost to Overweight by JPMorgan, from Neutral.</li>    <li>That comes in the wake of the company's <a href=\"https://seekingalpha.com/news/3503881-avaya-plus-11-percent-ringcentral-partnership\" target=\"_blank\">partnership with Avaya</a> (<a href='https://seekingalpha.com/symbol/AVYA' title='Avaya Holdings Corp.'>AVYA</a>, <font color=\"green\">up 1.9%</font> premarket).</li>    <li>That brings the chance to \"dramatically accelerate the shift to cloud-based [Unified Communication as a Service],\" JPMorgan says.</li>    <li>It's raised its price target on <a href='https://seekingalpha.com/symbol/RNG' title='RingCentral, Inc.'>RNG</a> to $225 from $143, implying 38% upside.</li>    <li>Sell-side analysts rate <a href='https://seekingalpha.com/symbol/RNG' title='RingCentral, Inc.'>RNG</a> a <a href=\"https://seekingalpha.com/symbol/RNG/ratings/sell-side-ratings\" target=\"_blank\">Buy on average</a>, and <a href=\"https://seekingalpha.com/symbol/RNG/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Bullish</a>; it has a <a href=\"https://seekingalpha.com/symbol/RNG/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504192\" data-linked=\"RingCentral +5.9% as JPMorgan upgrades to Overweight\" data-tweet=\"$RNG $AVYA - RingCentral +5.9% as JPMorgan upgrades to Overweight https://seekingalpha.com/news/3504192-ringcentralplus-5_9-jpmorgan-upgrades-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3504192-ringcentralplus-5_9-jpmorgan-upgrades-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504190\" data-ts=\"1570454490\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504190-roku-walmart-launch-soundbar-and-subwoofer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku, Walmart launch soundbar and subwoofer</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku, Inc.'>ROKU</a>) is <font color=\"green\">up 1.7%</font> premarket after the company announces with Walmart (NYSE:<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a>) a <a href=\"https://seekingalpha.com/pr/17654773-walmart-roku-announce-new-onn-roku-smart-soundbar-onn-roku-wireless-subwoofer\" target=\"_blank\">smart soundbar and subwoofer</a>, to add premium sound and streaming ability to any television.</li>    <li>Each of the two \"Onn\" branded products will be exclusive to Walmart stores and Walmart.com and retail for $129.</li>    <li>The soundbar adds sound and streaming to televisions with HDMI inputs and HDMI-ARC or optical audio output. The optional subwoofer adds rich bass and pairs with the soundbar.</li>    <li>The products will be available in coming weeks.</li>    <li><a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a> is <font color=\"green\">up 0.2%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504190\" data-linked=\"Roku, Walmart launch soundbar and subwoofer\" data-tweet=\"$ROKU $WMT - Roku, Walmart launch soundbar and subwoofer https://seekingalpha.com/news/3504190-roku-walmart-launch-soundbar-and-subwoofer?source=tweet\" data-url=\"https://seekingalpha.com/news/3504190-roku-walmart-launch-soundbar-and-subwoofer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504186\" data-ts=\"1570454353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSW\" target=\"_blank\">INSW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504186-international-seaways-sells-ownership-in-qatar-lng-jv-for-123m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Seaways sells ownership in Qatar LNG JV for $123M</a></h4><ul><li>International Seaways (NYSE:<a href='https://seekingalpha.com/symbol/INSW' title='International Seaways, Inc.'>INSW</a>) <font color=\"green\">+5.8%</font> pre-market after <a href=\"https://seekingalpha.com/pr/17654613-international-seaways-announces-sale-ownership-interest-lng-joint-venture\" target=\"_blank\">agreeing to sell</a> its 49.9% ownership interest in its joint venture with Qatar Gas Transport, or Nakilat, back to the company for $123M.</li><li>Nakilat owns four liquefied natural gas carriers on long-term charters for LNG export from Qatar.</li><li>INSW says the sale will strengthen its balance sheet and further its capital allocation strategy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504186\" data-linked=\"International Seaways sells ownership in Qatar LNG JV for $123M\" data-tweet=\"$INSW - International Seaways sells ownership in Qatar LNG JV for $123M https://seekingalpha.com/news/3504186-international-seaways-sells-ownership-in-qatar-lng-jv-for-123m?source=tweet\" data-url=\"https://seekingalpha.com/news/3504186-international-seaways-sells-ownership-in-qatar-lng-jv-for-123m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504182\" data-ts=\"1570454187\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NGM\" target=\"_blank\">NGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504182-ngm-bio-down-17-premarket-on-underwhelming-data-on-nash-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NGM Bio down 17% premarket on underwhelming data on NASH candidate</a></h4><ul><li>Thinly traded NGM Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/NGM' title='NGM Biopharmaceuticals, Inc.'>NGM</a>) is down <font color=\"red\">17% </font>premarket on light volume in apparent reaction to preliminary <a href=\"https://seekingalpha.com/pr/17654539-ngm-bio-announces-positive-interim-results-ongoing-24-week-phase-2-study-evaluating\" target=\"_blank\">24-week data</a> from Cohort 4 in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03912532?lead=ngm+biopharmaceuticals&amp;rank=3\" target=\"_blank\">Phase 2 clinical trial</a> evaluating daily 1 mg doses of aldafermin in NASH patients.</li><li>Absolute liver fat content dropped 7.9% in treated patients compared to a reduction of 2.0% in the placebo arm (p&lt;0.05). The relative reduction was -39.6% versus -5.9% for control (p&lt;0.05).</li><li>The results appear to be shy of Viking Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics, Inc.'>VKTX</a>) <a href=\"https://seekingalpha.com/news/3449927-viking-ahead-7-percent-premarket-new-vk2809-data\" target=\"_blank\">VK2809 </a>and similar to Madrigal Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a>) <a href=\"https://seekingalpha.com/news/3408553-madrigal-pharma-3-percent-positive-mid-stage-mglminus-3196-data\" target=\"_blank\">MGL-3196</a>.</li><li>On the safety front, the most common treatment-related adverse events (mostly mild/moderate) were diarrhea, headache, nausea and joint pain.</li><li>Topline data should be available in Q1 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504182\" data-linked=\"NGM Bio down 17% premarket on underwhelming data on NASH candidate\" data-tweet=\"$NGM $VKTX $MDGL - NGM Bio down 17% premarket on underwhelming data on NASH candidate https://seekingalpha.com/news/3504182-ngm-bio-down-17-premarket-on-underwhelming-data-on-nash-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3504182-ngm-bio-down-17-premarket-on-underwhelming-data-on-nash-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504181\" data-ts=\"1570454119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504181-spwr-fro-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SPWR, FRO among premarket gainers</a></h4><ul><li>Pfenex (NYSEMKT:<a href='https://seekingalpha.com/symbol/PFNX' title='Pfenex Inc.'>PFNX</a>) <font color=\"green\">+13%</font> as <a href=\"https://seekingalpha.com/news/3504130-fda-oks-pfenex-forteo-biosimilar-shares-9-percent-premarket\" target=\"_blank\">FDA OKs</a> Pfenex Forteo biosimilar.</li><li>Mereo BioPharma Group plc (NASDAQ:<a href='https://seekingalpha.com/symbol/MREO' title='Mereo BioPharma Group plc'>MREO</a>) <font color=\"green\">+11%</font> on navicixizumab <a href=\"https://seekingalpha.com/news/3504171-mereo-bios-navicixizumab-fast-trackd-ovarian-cancer-shares-6-percent-premarket\" target=\"_blank\">Fast Track'd</a> for ovarian cancer</li><li>Livongo Health (NASDAQ:<a href='https://seekingalpha.com/symbol/LVGO' title='Livongo Health, Inc.'>LVGO</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/pr/17654412-livongo-awarded-diabetes-contract-eligible-population-approximately-5_3-million-beneficiaries\" target=\"_blank\">awarding</a> diabetes contract for eligible population for ~5.3M</li><li>Innovate Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INNT' title='Innovate Biopharmaceuticals, Inc.'>INNT</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/pr/17654324-innovate-biopharmaceuticals-merge-rdd-pharma-creating-new-gastroenterology-company-focused\" target=\"_blank\">merging</a> with RDD Pharma creating new Gastroenterology company focused on specialty, rare and orphan diseases.</li><li>International Seaways (NYSE:<a href='https://seekingalpha.com/symbol/INSW' title='International Seaways, Inc.'>INSW</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/pr/17654613-international-seaways-announces-sale-ownership-interest-lng-joint-venture\" target=\"_blank\">sale of ownership</a> interest in LNG JV.</li><li>Teekay Tankers (NYSE:<a href='https://seekingalpha.com/symbol/TNK' title='Teekay Tankers Ltd.'>TNK</a>) <font color=\"green\">+6%</font>.</li><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"green\">+6%</font>.</li><li>Frontline (NYSE:<a href='https://seekingalpha.com/symbol/FRO' title='Frontline Ltd.'>FRO</a>) <font color=\"green\">+6%</font>.</li><li>InMode (NASDAQ:<a href='https://seekingalpha.com/symbol/INMD' title='InMode Ltd.'>INMD</a>) <font color=\"green\">+6%</font>.</li><li>SunPower (NASDAQ:<a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a>) <font color=\"green\">+6%</font>.</li><li>RingCentral (NYSE:<a href='https://seekingalpha.com/symbol/RNG' title='RingCentral, Inc.'>RNG</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504181\" data-linked=\"SPWR, FRO among premarket gainers\" data-tweet=\"$PFNX $MREO $LVGO - SPWR, FRO among premarket gainers https://seekingalpha.com/news/3504181-spwr-fro-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3504181-spwr-fro-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504180\" data-ts=\"1570454113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLAD\" target=\"_blank\">GLAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504180-gladstone-capital-plans-offering-of-2024-notes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gladstone Capital plans offering of 2024 notes</a></h4><ul><li>Gladstone Capital (NASDAQ:<a href='https://seekingalpha.com/symbol/GLAD' title='Gladstone Capital'>GLAD</a>) plans a <a href=\"https://seekingalpha.com/pr/17654862-gladstone-capital-corporation-announces-notes-offering\" target=\"_blank\">public offering </a>of notes due 2024 and intends to use net proceeds to repay part of the amount outstanding under its credit facility, to fund new investment opportunities, and for other general corporate purposes.</li><li>Gladstone Capital <font color=\"green\">gains 1.2%</font> in premarket trading.</li><li>Plans to list notes on the Nasdaq Global Select Market under the trading symbol \"GLADL\" within 30 days of issuance.</li><li><a href=\"https://seekingalpha.com/filing/4659057\" target=\"_blank\">SEC filing</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504180\" data-linked=\"Gladstone Capital plans offering of 2024 notes\" data-tweet=\"$GLAD - Gladstone Capital plans offering of 2024 notes https://seekingalpha.com/news/3504180-gladstone-capital-plans-offering-of-2024-notes?source=tweet\" data-url=\"https://seekingalpha.com/news/3504180-gladstone-capital-plans-offering-of-2024-notes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504178\" data-ts=\"1570453737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COP\" target=\"_blank\">COP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504178-conocophillips-pops-after-lifting-dividend-planning-3b-stock-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConocoPhillips pops after lifting dividend, planning $3B stock buyback</a></h4><ul><li>ConocoPhillips (NYSE:<a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a>) <font color=\"green\">+1.5%</font> pre-market after <a href=\"https://seekingalpha.com/pr/17654659-conocophillips-announces-38-percent-increase-quarterly-dividend-expects-repurchase-3-billion\" target=\"_blank\">raising its quarterly dividend</a> to $0.42/share and unveiling plans to repurchase $3B worth of common shares in 2020.</li><li>The 38% dividend increase \"reflects the significant  transformation our company has undergone over the past few years,\" Chairman and CEO Ryan Lance says.</li><li>COP says it will present a 10-year outlook at next month's Investor Day to include a capital  investment plan, a financial framework  focused on free cash flow generation and a commitment to both returns  on capital employed and returns of capital to shareholders.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504178\" data-linked=\"ConocoPhillips pops after lifting dividend, planning $3B stock buyback\" data-tweet=\"$COP - ConocoPhillips pops after lifting dividend, planning $3B stock buyback https://seekingalpha.com/news/3504178-conocophillips-pops-after-lifting-dividend-planning-3b-stock-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3504178-conocophillips-pops-after-lifting-dividend-planning-3b-stock-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504177\" data-ts=\"1570453695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504177-xent-capr-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XENT, CAPR among premarket losers</a></h4><ul><li>Intersect ENT XENT <font color=\"red\">-16%</font> on <a href=\"https://seekingalpha.com/news/3504148-intersect-ent-26-percent-premarket-failed-study-drug-coated-sinus-balloon\" target=\"_blank\">failed</a> study of drug-coated sinus balloon.</li><li>Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"red\">-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504177\" data-linked=\"XENT, CAPR among premarket losers\" data-tweet=\"$CAPR - XENT, CAPR among premarket losers https://seekingalpha.com/news/3504177-xent-capr-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3504177-xent-capr-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504171\" data-ts=\"1570452669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MREO\" target=\"_blank\">MREO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504171-mereo-bios-navicixizumab-fast-trackd-for-ovarian-cancer-shares-up-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mereo Bio&#39;s navicixizumab Fast Track&#39;d for ovarian cancer; shares up 6% premarket</a></h4><ul><li>Thinly traded nano cap Mereo BioPharma Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MREO' title='Mereo BioPharma Group plc'>MREO</a>) is up <font color=\"green\">6%</font> premarket on increased volume, albeit on turnover of only 29K shares, in reaction to <a href=\"https://seekingalpha.com/pr/17654586-mereo-biopharma-receives-fda-fast-track-designation-navicixizumab-treatment-heavily\" target=\"_blank\">Fast Track designation</a> in the U.S. for Phase 1-stage bispecific antibody navicixizumab for heavily pretreated patients with high grade ovarian, primary peritoneal or fallopian tube cancer who have received at least three prior lines of therapy and/or prior treatment with Roche's Avastin (bevacizumab).</li><li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li><li>Celgene was investigating the candidate but <a href=\"https://seekingalpha.com/news/3398262-oncomed-pharma-8-percent-hours-celgene-withdrawal-rosmantuzumab\" target=\"_blank\">declined </a>to exercise its license option about a year ago.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504171\" data-linked=\"Mereo Bio&#39;s navicixizumab Fast Track&#39;d for ovarian cancer; shares up 6% premarket\" data-tweet=\"$MREO - Mereo Bio&#39;s navicixizumab Fast Track&#39;d for ovarian cancer; shares up 6% premarket https://seekingalpha.com/news/3504171-mereo-bios-navicixizumab-fast-trackd-for-ovarian-cancer-shares-up-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3504171-mereo-bios-navicixizumab-fast-trackd-for-ovarian-cancer-shares-up-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504160\" data-ts=\"1570450826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQBG\" target=\"_blank\">SQBG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504160-sequential-brands-to-explore-strategic-options\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sequential Brands to explore strategic options</a></h4><ul> <li>Sequential Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) announces that its board is conducting a broad review of strategic alternatives focused on maximizing shareholder value.</li><li>The company says the strategic alternatives may include the divestiture of one or more existing brands, the acquisition of one or more new brands, a stock buyback program, and other initiatives.</li><li>Stifel has been engaged to assist Sequential Brands in the process.</li>   <li>\"After having received unsolicited interest for several of our brands from multiple parties, Sequential\u2019s Board of Directorsshareholders,\" notes Sequential Chairman William Sweedler. is engaging in this formal process to ensure that we are evaluating all alternatives to best further the interest of our</li>  <li>In addition, Karen Murray has stepped down as director and CEO of the Company. Murray will continue to serve as senior advisor and assist the company on strategic opportunities.</li><li>SQBG  <font color=\"green\">+5.65%</font> premarket to  $0.28.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17654541-sequential-brands-group-announces-exploration-strategic-alternatives-leadership-transition\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3504160\" data-linked=\"Sequential Brands to explore strategic options\" data-tweet=\"$SQBG - Sequential Brands to explore strategic options https://seekingalpha.com/news/3504160-sequential-brands-to-explore-strategic-options?source=tweet\" data-url=\"https://seekingalpha.com/news/3504160-sequential-brands-to-explore-strategic-options\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504150\" data-ts=\"1570449557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504150-nvidiaplus-1_3-after-rbc-price-target-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia +1.3% after RBC price target boost</a></h4><ul> <li>RBC Capital Markets lifts its price target on Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) to $217 from $190 vs. the <a href=\"https://seekingalpha.com/symbol/NVDA/ratings/sell-side-ratings?s=nvda\" target=\"_blank\">sell-side average PT</a> of $186.03.</li> <li>RBC bases the price target hike off Nvidia's improving gaming GPU demand and conviction over Q4 improvement in the data center business.</li> <li>\"We believe that we're past the bottom from a demand perspective,\" notes RBC analyst Mitch Steves.</li> <li>Shares of Nvidia are <font color=\"green\">up 1.28%</font> premarket to $184.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504150\" data-linked=\"Nvidia +1.3% after RBC price target boost\" data-tweet=\"$NVDA - Nvidia +1.3% after RBC price target boost https://seekingalpha.com/news/3504150-nvidiaplus-1_3-after-rbc-price-target-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3504150-nvidiaplus-1_3-after-rbc-price-target-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504149\" data-ts=\"1570449390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504149-pair-of-upgrades-sends-match-up-nearly-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">A pair of upgrades sends Match up nearly 4%</a></h4><ul><li>Seeing limited impact from FTC's recent lawsuit against the company, Nomura's Mark Kelly upgrades Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) to Buy from Neutral. He says the suggested $60M fine is \"insignificant.\" Alongside the upgrade, Kelly lifts his price target to $88 from $81.</li><li>Also upgrading to Buy this morning is Deutsche Bank.</li><li>Shares are <font color=\"green\">higher by 3.8%</font> premarket to $77.52.</li><li>While the average Sell-Side rating on Match is Outperform, the <a href=\"https://seekingalpha.com/symbol/MTCH/ratings/author-ratings#filter=all\" target=\"_blank\">SA Authors average rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504149\" data-linked=\"A pair of upgrades sends Match up nearly 4%\" data-tweet=\"$MTCH - A pair of upgrades sends Match up nearly 4% https://seekingalpha.com/news/3504149-pair-of-upgrades-sends-match-up-nearly-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3504149-pair-of-upgrades-sends-match-up-nearly-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504148\" data-ts=\"1570449326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XENT\" target=\"_blank\">XENT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504148-intersect-ent-down-26-premarket-on-failed-study-of-drug-coated-sinus-balloon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intersect ENT down 26% premarket on failed study of drug-coated sinus balloon</a></h4><ul><li>Intersect ENT (NASDAQ:<a href='https://seekingalpha.com/symbol/XENT' title='Intersect ENT, Inc.'>XENT</a>) slumps <font color=\"red\">26%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17654366-intersect-ent-announces-results-ascend-study-company-s-investigational-drug-coated-balloon\" target=\"_blank\">unsuccessful results</a> from the randomized ASCEND study evaluating its drug-coated sinus balloon for dilating the frontal sinus ostium to reduce post-balloon dilation edema via the localized delivery of steroid directly to dilated tissue.</li><li>The drug-coated sinus balloon failed to beat an uncoated balloon control as measured by sinus patency grade at day 30, the primary endpoint. Several secondary endpoints were met, including reductions in inflammation and polypoid edema.</li><li>No safety signals were observed.</li><li>The company will further analyze the results before deciding on next steps.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504148\" data-linked=\"Intersect ENT down 26% premarket on failed study of drug-coated sinus balloon\" data-tweet=\"$XENT - Intersect ENT down 26% premarket on failed study of drug-coated sinus balloon https://seekingalpha.com/news/3504148-intersect-ent-down-26-premarket-on-failed-study-of-drug-coated-sinus-balloon?source=tweet\" data-url=\"https://seekingalpha.com/news/3504148-intersect-ent-down-26-premarket-on-failed-study-of-drug-coated-sinus-balloon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504143\" data-ts=\"1570448463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504143-uberplus-3-after-citi-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uber +3% after Citi upgrade</a></h4><ul> <li>Citi lifts Uber Technologies (NYSE:<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a>) to a Buy rating after having it slotted at Neutral.</li> <li>The firm is more comfortable with Uber's track forward even with overhangs such as California Assembly Bill 5 and the IPO share lock-up still lingering.</li> <li>Citi's price target of $45 is still short of the consensus sell-side PT of $49.58.</li> <li>Shares of Uber are <font color=\"green\">up 3.24%</font> premarket to $30.63.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504143\" data-linked=\"Uber +3% after Citi upgrade\" data-tweet=\"$UBER - Uber +3% after Citi upgrade https://seekingalpha.com/news/3504143-uberplus-3-after-citi-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3504143-uberplus-3-after-citi-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504141\" data-ts=\"1570448317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDC\" target=\"_blank\">SDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504141-sell-siders-waving-pom-poms-on-smiledirectclub-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-siders waving pom-poms on SmileDirectClub in premarket analyst action</a></h4><ul><li>Brushing aside questions on its teledentistry platform and concerns with governance issues, sell-side analysts rush in with bullish ratings on SmileDirectClub (NASDAQ:<a href='https://seekingalpha.com/symbol/SDC' title='SmileDirectClub, Inc.'>SDC</a>) in an attempt to salvage the company's tepid IPO. Shares are down <font color=\"red\">36%</font> from the $23 offer price. New coverage: Buy rating and $19 (29% upside) price target at BofA Merrill Lynch, Buy rating and $19 price target at Citigroup, Buy rating and $24 price target at Guggenheim, Buy rating and $22 price target at Jefferies, Buy rating and $19 price target at Stifel, Outperform rating and $18 price target at Credit Suisse, Outperform rating at William Blair, Overweight rating and $21 price target at JPMorgan. Shares up <font color=\"green\">3%</font> premarket.</li><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) initiated with Market Perform rating at JMP Securities.</li><li>Sutro Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/STRO' title='Sutro Biopharma, Inc.'>STRO</a>) initiated with Buy rating and $19 (125% upside) price target at BTIG Research.</li><li>10x Genomics (NASDAQ:<a href='https://seekingalpha.com/symbol/TXG' title='10x Genomics, Inc.'>TXG</a>) initiated with Buy rating and $62 (21% upside) price target at BofA Merrill Lynch.</li><li>Zimmer Biomet Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZBH' title='Zimmer Biomet Holdings, Inc.'>ZBH</a>) upgraded to Buy with a $158 (18% upside) price target at BTIG Research.</li><li>Akcea Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics, Inc.'>AKCA</a>) upgraded to Outperform with a $25 (65% upside) price target at Wells Fargo. Shares up <font color=\"green\">22%</font> premarket on out-licensing of AKCEA-ANGPTL3-Lrx to Pfizer.</li><li>Align Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/ALGN' title='Align Technology, Inc.'>ALGN</a>) downgraded to Neutral with a $200 (10% upside) price target at Guggenheim.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504141\" data-linked=\"Sell-siders waving pom-poms on SmileDirectClub in premarket analyst action\" data-tweet=\"$SDC $SRNE $STRO - Sell-siders waving pom-poms on SmileDirectClub in premarket analyst action https://seekingalpha.com/news/3504141-sell-siders-waving-pom-poms-on-smiledirectclub-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3504141-sell-siders-waving-pom-poms-on-smiledirectclub-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504136\" data-ts=\"1570446720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDC\" target=\"_blank\">SDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504136-smiledirectclubplus-3-positive-ratings-pour-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SmileDirectClub +3% as positive ratings pour in</a></h4><ul> <li>Analyst coverage on SmileDirectClub (NASDAQ:<a href='https://seekingalpha.com/symbol/SDC' title='SmileDirectClub, Inc.'>SDC</a>) arrives overwhelmingly on the bullish side.</li> <li>Buy-equivalent rating are in from Bank of America Merrill Lynch (price target $19), Citi ($19 PT), Guggenheim ($24 PT), Jefferies ($22 PT), Stifel ($19 PT), Credit Suisse ($18 PT) and JPMorgan ($31 PT).</li> <li>Shares of SmileDirectClub are <font color=\"green\">up 3.26%</font> premarket to $15.20. The post-IPO is $21.10.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3504136\" data-linked=\"SmileDirectClub +3% as positive ratings pour in\" data-tweet=\"$SDC - SmileDirectClub +3% as positive ratings pour in https://seekingalpha.com/news/3504136-smiledirectclubplus-3-positive-ratings-pour-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3504136-smiledirectclubplus-3-positive-ratings-pour-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504135\" data-ts=\"1570446691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504135-capricor-up-15-premarket-on-new-capminus-1002-data-in-dmd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capricor up 15% premarket on new CAP-1002 data in DMD</a></h4><ul><li>Nano cap Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) is up <font color=\"green\">15%</font> premarket on modest volume in reaction to <a href=\"https://seekingalpha.com/pr/17654342-capricor-presents-additional-positive-data-ongoing-hopeminus-2-study-capminus-1002-duchenne\" target=\"_blank\">additional six-month data</a> on Duchenne muscular dystrophy &#40;DMD&#41; candidate CAP-1002 from the ongoing Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03406780?lead=capricor&amp;phase=1&amp;rank=1\" target=\"_blank\">HOPE-2</a> study. The results were presented at the World Muscle Society Congress in Copenhagen.</li><li>Participants receiving multiple doses of CAP-1002 showed improvements in a measure of shoulder, elbow, wrist and hand function called Performance of the Upper Limb &#40;PUL&#41;, the primary efficacy endpoint that will support a U.S. marketing application. The PUL scale is used in DMD patients unable to perform the six-minute walk test.</li><li>The company will host a conference call this morning at 8:30 am ET to discuss the results.</li><li><strong>Update</strong>: Share have reversed, now down <font color=\"red\">17%</font> premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504135\" data-linked=\"Capricor up 15% premarket on new CAP-1002 data in DMD\" data-tweet=\"$CAPR - Capricor up 15% premarket on new CAP-1002 data in DMD https://seekingalpha.com/news/3504135-capricor-up-15-premarket-on-new-capminus-1002-data-in-dmd?source=tweet\" data-url=\"https://seekingalpha.com/news/3504135-capricor-up-15-premarket-on-new-capminus-1002-data-in-dmd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504133\" data-ts=\"1570446357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504133-geplus-2_6-amid-pension-plan-freeze\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE +2.6% amid pension plan freeze</a></h4><ul><li>Looking to cut its huge debt pile, General Electric (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric Company'>GE</a>) is <a href=\"https://seekingalpha.com/pr/17654346-ge-announces-u-s-pension-plan-actions\" target=\"_blank\">freezing</a> pension plans for about 20,000 U.S. employees with salaried benefits.</li><li>The action, which will also suspend supplementary pension benefits for about 700 employees in the country, is expected to reduce GE's pension deficit by about $5B-$8B and net debt between $4B-$6B.</li><li>GE <font color=\"green\">+2.6%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3504133\" data-linked=\"GE +2.6% amid pension plan freeze\" data-tweet=\"$GE - GE +2.6% amid pension plan freeze https://seekingalpha.com/news/3504133-geplus-2_6-amid-pension-plan-freeze?source=tweet\" data-url=\"https://seekingalpha.com/news/3504133-geplus-2_6-amid-pension-plan-freeze\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>287&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504131\" data-ts=\"1570446007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XENT\" target=\"_blank\">XENT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504131-intersect-ent-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intersect ENT halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Intersect ENT (NASDAQ:<a href='https://seekingalpha.com/symbol/XENT' title='Intersect ENT, Inc.'>XENT</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504131\" data-linked=\"Intersect ENT halted pending news\" data-tweet=\"$XENT - Intersect ENT halted pending news https://seekingalpha.com/news/3504131-intersect-ent-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3504131-intersect-ent-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504130\" data-ts=\"1570445811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFNX\" target=\"_blank\">PFNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504130-fda-oks-pfenex-forteo-biosimilar-shares-up-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Pfenex Forteo biosimilar; shares up 9% premarket</a></h4><ul><li>Under its 505(b)(2) pathway, the FDA <a href=\"https://seekingalpha.com/pr/17654286-pfenex-receives-u-s-fda-approval-pf708-treat-osteoporosis\" target=\"_blank\">approves </a>Pfenex's (NYSEMKT:<a href='https://seekingalpha.com/symbol/PFNX' title='Pfenex Inc.'>PFNX</a>) PF708, a biosimilar to Eli Lilly's (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) osteoporosis med Forteo (teriparatide injection), for certain patients at high risk of fracture.</li><li>Licensee Alvogen will manufacture and commercialize.</li><li>Per the agency's request, Pfenex is conducting a comparative human factors study, expected to wind up this month, that it believes completes the data package to support PF708's therapeutic equivalence to Forteo.</li><li>Shares up <font color=\"green\">9%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504130\" data-linked=\"FDA OKs Pfenex Forteo biosimilar; shares up 9% premarket\" data-tweet=\"$PFNX $LLY - FDA OKs Pfenex Forteo biosimilar; shares up 9% premarket https://seekingalpha.com/news/3504130-fda-oks-pfenex-forteo-biosimilar-shares-up-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3504130-fda-oks-pfenex-forteo-biosimilar-shares-up-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3504125\" data-ts=\"1570441795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3504125-futures-start-week-on-back-foot\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Futures start week on back foot</a></h4><ul><li>Broadly positive U.S. jobs data has quelled some fears about an economic slowdown, but nervousness over U.S.-China trade talks is setting in, as well as more weak <a href=\"https://seekingalpha.com/news/3504121-germanys-factory-slump-continues\" target=\"_blank\">economic data</a> out of Europe.</li><li>The mood is weighing again on U.S. stock index futures, which have started the week <font color=\"red\">down 0.5%</font>.</li><li>While Chinese Vice Premier Liu He is expected to resume discussions with U.S. counterparts later this week, there have been a number of reports that Beijing may not be as willing to compromise on a number of issues or <a href=\"https://www.cnbc.com/2019/10/06/china-is-reportedly-reluctant-to-agree-to-a-broad-us-trade-deal-with-talks-set-to-restart.html\" target=\"_blank\">agree</a> to a broad trade deal pursued by President Trump.</li></ul><div class=\"tiny-share-widget\" data-id=\"3504125\" data-linked=\"Futures start week on back foot\" data-tweet=\"Futures start week on back foot https://seekingalpha.com/news/3504125-futures-start-week-on-back-foot?source=tweet\" data-url=\"https://seekingalpha.com/news/3504125-futures-start-week-on-back-foot\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":57,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}